Winthrop KL, et al. – The experts wished to figure out whether concomitant conventional synthetic disease–modifying antirheumatic drugs (csDMARDs) or glucocorticoids contribute to increased herpes zoster (HZ) risk with tofacitinib. Findings displayed that patients receiving tofacitinib with glucocorticoids had a greater risk of developing HZ compared to patients using tofacitinib monotherapy without glucocorticoids.